Reproducibility and Utility of OGTT in Acromegaly

Learn more about:
Related Clinical Trial
Rhinological Outcomes in Endonasal Pituitary Surgery Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma Study in Polish Acromegalic Patients Treated With Somatuline Autogel Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery The Observational Study of Growth Hormone-secreting Pituitary Tumors Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Phase II Study With ITF2984 in Acromegalic Patients Non Interventional Study For Patients Treated With Somavert® Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. Estrogen Treatment in Acromegalic Women Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A. ACRODAT Prospective Evaluation Study Pegvisomant And Sandostatin LAR Combination Study Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Canadian Pegvisomant Compassionate Study In Acromegalic Patients Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Tissue Biomarker for Pegvisomant Action Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Predictive Factors Study Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Acromegaly – Before and After Treatment Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly Measurement of Outcome of Surgical Treatment in Patients With Acromegaly Non Interventional Post Marketing Programme in Acromegaly Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Cardiovascular Outcome After Surgery or Somatostatin Analogues Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Long Term Study With B2036-PEG Octreotide Efficacy and Safety in First-line Acromegalic Patients Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly Clomiphene Citrate for Treatment of Acromegaly Cardiac (CMRI) Assessment of Acromegaly Acromegaly Combination Treatment Study Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Pasireotide LAR and Pegvisomant Study in Acromegaly Effects of Sandostatin LAR® in Acromegaly Open Label Study of Octreotide Implant in Patients With Acromegaly Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Somatuline Autogel: Acromegaly Self/Partner Injection Study A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly Prospective Study on Changes in Acromegaly Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment. A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing’s Disease or Acromegaly Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Rehabilitation Program in Patients With Acromegaly Acute Application of Pegvisomant and Octreotide in Acromegaly Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Prediction of Tumor Shrinkage in Acromegaly Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly SAGIT for Classification of Patients With Acromegaly in Clinical Practice Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients Late Effects of Radiosurgery on Acromegaly Study Ultrasound Guided Octreotide LAR Injection in Acromegaly Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly Strict IGF-1 Control in Acromegaly Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Fractionated Stereotactic Radiotherapy in Patients With Acromegaly Validation Study of the SAGIT® Instrument in Acromegaly Developing a Simple Recognition System of Acromegaly Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance Surgical Versus Medical Treatment of Acromegaly A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Acromegaly & Sleep Apnoea Somatuline Predictive Factors in Acromegaly and NET Acromegaly Treatment Quality of Life Study Lanreotide Levels in Acromegaly Description of Sign-and-symptom Associations at Acromegaly Diagnosis. Treatment Patterns and Treatment Outcomes for Acromegaly Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly Physiopathology of Sodium Retention in Acromegaly Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study Peri- and Post-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly During the First Year After Surgical Resection The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research Preoperative Octreotide Treatment of Acromegaly The Treatment and Natural History of Acromegaly Bone MicroArchitecture in Acromegaly Reproducibility and Utility of OGTT in Acromegaly A Prospective Study of Outcome After Therapy for Acromegaly Epidemiology of Acromegaly in Denmark 1991-2010 Programme of Acromegaly Screening in Patients With Associated Somatic Disorders Acromegaly: Patient And Physician Perspectives

Brief Title

Reproducibility and Utility of OGTT in Acromegaly

Official Title

Reproducibility and Utility of Growth Hormone Inhibition by Oral Glucose Tolerance Test for the Diagnosis of Acromegaly

Brief Summary

      Prospective study of reproducibility and utility of growth hormone inhibition by oral glucose
      tolerance test for the diagnosis of acromegaly, in acromegalic and non-acromegalic subjects,
      with a randomized double-blind crossover over placebo arm in the group of acromegalic

Detailed Description

      Rational: The initial step of biological diagnosis of acromegaly is based on assessment of
      IGF-I. According to current recommendations, the diagnosis must be confirmed by an oral
      glucose tolerance test (OGTT) to show that there is no growth hormone (GH) decrease lower
      than 1 μg/L (Katznelson , et al., 2014).

      Reproducibility of GH suppression by the OGTT has never been evaluated in either acromegalic
      or healthy subjects, although it is essential to determine the reliability of this test.
      Spontaneous fluctuations in GH in acromegaly could significantly influence the response of GH
      to the OGTT and cause low reproducibility of the test in this population. In particular, this
      reliability could be different according to the typical or moderate clinical presentation
      because of the persistence of a residual ultradian rhythm of GH secretion.

      The usefulness of oral glucose loading and the resulting hyperglycemia (which may limit GH
      secretion) has never been compared to an appropriate placebo (aspartame, at a dose equivalent
      to 75 g glucose), which does not cause hyperglycemia. Ingestion of 75 g of glucose is often
      responsible for nausea and vomiting. More rarely, the drop in blood glucose reactive to hyper
      insulinemia at the end of the test, can be the cause of discomfort.

      Primary objective: To determine the reproducibility of the GH response to OGTT in acromegaly
      by studying, in subjects with acromegaly, changes in GH concentration within 2 hours after
      oral administration of 75 g of glucose at 2 repeated tests in the same subject.

      Secondary objectives:

        1. To analyze the reproducibility of the GH response to the OGTT as a function of the
           severity of acromegaly ("typical" form, "intermediate" form of acromegaly) and in a
           group of non-acromegalic subjects.

        2. To evaluate the diagnostic value (utility) of OGTT in acromegaly by comparing, in
           subjects with acromegaly, the response of GH to oral administration of 75 g of glucose
           (OGTT) and 375 mg of aspartame (placebo).

        3. Evaluate OGTT-stimulated insulin secretion in acromegalic and non-acromegalic subjects.

Study Type


Primary Outcome

Compare Nadir GH concentration in μg/L obtained in two OGTT in the same subject with acromegaly

Secondary Outcome

 Severity of acromegaly ("typical" form, "intermediate" form of acromegaly)




Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam

Study Arms / Comparison Groups

 OGTT Tests and Placebo Test
Description:  Patients with acromegaly


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 10, 2019

Completion Date

December 10, 2022

Primary Completion Date

December 10, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Acromegalic subjects

          -  Men or women, adults ≤ 85 years, with hypersecretion of GH proven by the following

               -  High IGF-I compared to age and sex standards (Variety study, Chanson et al.,

               -  and basal GH concentrations > 0.4 μg / L (Katznelson, et al., 2014) and
                  somatotropic pituitary adenoma operated on or planned to be operated on. It may
                  be patients whose acromegaly has just been discovered and not yet treated (de
                  novo patients) for whom a surgical treatment is envisaged within 6 months after
                  inclusion or acromegalic patients already operated on a pituitary adenoma whose
                  acromegaly is not controlled by surgery. A histological confirmation of a
                  somatotropic pituitary adenoma will be obtained either before inclusion in the
                  study (subjects already operated) or after inclusion ("de novo" subjects) in
                  order to have a sufficient level of proof of the diagnosis of acromegaly,
                  especially in the "intermediate" forms.

          -  Medically treated patients who decide to discontinue treatment (in order to reassess
             the progression of the disease, or at the time of a change), will be eligible after
             more than 3 months of discontinuation of the drug treatment.

          -  In women on estrogen / progestin contraception, this should be kept unchanged
             throughout the study. In the absence of estrogen / progestin contraception,
             exploration will be done in the follicular phase.

        Non-acromegalic subjects:

          -  Men or women, adults ≤ 85 years

          -  Subjects defined by a concentration of IGF-I below 100% of the upper limit of normal,
             matched for sex and age (± 5 years) to acromegalic patients.

          -  Normal blood pressure measured by an electronic tensiometer validated after 5 min
             resting in supine position <140/90 mmHg on 3 consecutive measurements

          -  Biological assessment (hematological and biochemical blood tests, urine analysis)
             within the limits of normal or clinically acceptable. Normal EKG.

          -  ECG 12 leads without particularity.

          -  Affiliation to a social security scheme

          -  At the women on estrogen-progestative contraception, this one should be kept unchanged
             throughout the study. In the absence of estrogen-progestative contraception,the
             exploration will be done in the follicular phase.

          -  Signed informed consent.

        Exclusion Criteria:

        For both groups:

          -  Pregnant or breastfeeding women

          -  Acute systemic diseases

          -  Pathologies likely to affect digestive absorption

          -  Taking prohibited treatments (see section 7.3)

          -  History of hypersensitivity to aspartame (edema of Quincke, Urticaria ..)

          -  Donation of blood in the 3 months preceding the study

          -  People in the exclusion period on the national file people suitable for research
             involving the human person

          -  Refusal or linguistic or psychic incapacity to sign informed consent

          -  Subject unable to submit to the constraints of the protocol (for example,
             non-cooperating, unable to return to follow-up visits and probably unable to finish
             the study)

          -  Major under guardianship

          -  Major under curatorship

          -  People with phenylketonuria

          -  Person with digestive intolerance to glucose /galactose, digestive labsorption
             syndrome of glucose / galactose.

        For the group of acromegalic patients:

          -  acromegalic patients with diabetes mellitus treated with insulin

          -  Acromegalic patients under medical treatment of their acromegaly somatostatin
             analogues, pegvisomant), or patients in whom this treatment has been suspended for
             less than 3 months at the time of the selection.

          -  Acromegalic patients who have been treated with radiotherapy.

        For the group of non-acromegalic subjects:

        - Chronic systemic diseases likely to influence the secretion of GH like diabetes
        sweetness, severe obesity (BMI> 35 kg / m2), inadequate renal (creatinine clearance <60 mL
        / min), disease hypothalamic-pituitary, epilepsy, antecedents Hepatocellular insufficiency
        and insufficiency cardiac, progressive cancer.




18 Years - 85 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, 01 45 21 33 98, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Assistance Publique - Hôpitaux de Paris

Study Sponsor

, , 

Verification Date

August 2019